Kenneth J. Hillan

Molecular Biology · 2001–2005

A researcher in the Science corpus: 5 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 54 citations into it; #9,052 of 17,773 by trust here, #5,914 by citations
• Oncology — 32 citations into it; #653 of 1,698 by trust here, #526 by citations
• Cancer Research — 30 citations into it; #639 of 1,780 by trust here, #554 by citations
• Cell Biology — 9 citations into it
• Cellular and Molecular Neuroscience — 6 citations into it

Whom Kenneth J. Hillan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. N. Ferrara
2. Rakesh K. Jain

Who trusts Kenneth J. Hillan overall

1. N. Ferrara
2. J. Joyce
3. R. Apte
4. Michael W. Pickup
5. Ji Luo

Papers from Kenneth J. Hillan's perspective

Ordered by how strongly the researchers Kenneth J. Hillan trusts endorse each paper. Same corpus, a different order for every researcher.

1. Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)
2. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
3. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (Nature Medicine)
4. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (Journal of Clinical Investigation)
5. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. (Journal of Clinical Oncology)
6. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. (Journal of Clinical Oncology)
7. VEGF-Trap: A VEGF blocker with potent antitumor effects (Proceedings of the National Academy of Sciences of the United States of America)
8. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. (Journal of Clinical Investigation)
9. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug (Nature reviews. Drug discovery)
10. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. (Journal of Clinical Oncology)

Their papers

• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) — 2,638 citations
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions (2001) — 757 citations
• Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. (2005) — 1,036 citations
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. (2005) — 1,504 citations
• Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 (2003) — 688 citations